ViiV SOLAR Study at DAP: Injectable ART every 2-Months
Diversity was key in choosing participants
DAP Health is one of the few health centers in the U.S. working on a study using only six injections per year for maintaining viral suppression in people with HIV (PWH). The SOLAR study with ViiV Healthcare began in November and will last one year.
The FDA approved once-monthly Cabenuva injections to treat HIV in January 2021.
At this time, the participant panel is complete, and no applications are being accepted.
For some PWH, taking medication in pill form every day is difficult, and it can cause poor adherence that harms their health and puts others at risk. Traditional HIV meds can also lead to side effects with long term use.
Participants in the SOLAR Study at DAP will receive intramuscular (IM) injections of CABENUVA every two months for HIV treatment. This regimen is not publicly available, but it holds a lot of promise for DAP patients, according to Dr. Tulika Singh, DAP director of research.
It was important to Dr. Singh that the SOLAR Study at DAP includes participants who are usually underrepresented in HIV research: cisgender women and transgender women.
“With the help of this study, we are able to start closing a research gap,” said Dr. Singh, “and we can contribute to serving these patient groups better.”
Specifically, this phase IIIb, randomized, multicenter, parallel-group, non-inferiority, open-label study will evaluate the efficacy, safety, and tolerability of switching to long-acting Cabotegravir plus long-acting Rilpivirine from a Bictegravir single tablet regimen in HIV-1 infected adults who are virologically suppressed.
Once-Monthly CABENUVA is Available in Canada
Health Canada approved a once-monthly version of CABENUVA for use there in March. CABENUVA is the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults to replace traditional antiretroviral therapy.
About DAP Health
DAP Health (DAP) is an advocacy-based health center in Palm Springs, CA serving over 8,000 patients, offering medical and mental healthcare, STI testing and treatment, dentistry, pharmacy, and lab. A variety of wraparound services enable patients to experience optimal health, including social services, support groups, alternative therapies, and other wellness services. Excellent HIV care is provided by the largest team of specialized clinicians in the area.
DAP opened one of California’s first COVID clinic and hotlines to offer screening, testing, and treatment. DAP is also working to address social determinants of health that are causing negative health outcomes during this pandemic, like food and housing insecurity, joblessness, isolation, and access to ongoing healthcare.
DAP’s sexual health clinic offers STI testing and treatment, Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), and HIV and HCV testing. DAP has earned Charity Navigator’s highest rating for the twelfth consecutive year – landing DAP in the top 6% of nonprofits rated. The distinction recognizes that DAP exceeds industry standards in terms of financial health, accountability, and transparency.
Visit www.daphealth.org to learn more.
About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined in October 2012. The company’s aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline and commitment, please visit www.viivhealthcare.com.
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com.